Adderall, drug with stimulatory effects on the central nervous system that is prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The pharmaceutical company Rexar reformulated their weight loss drug Obetrol following its mandatory withdrawal from the market in 1973, under the Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act due to the results of the Drug Efficacy Study Implementation (DESI) program (which indicated a lack of efficacy). The new formulation simply replaced the two methamphetamine components with dextroamphetamine and amphetamine components of the same weight (the other two original dextroamphetamine and amphetamine components were preserved), preserved the Obetrol branding, and despite it lacking FDA approval, it still made it onto the market and was marketed and sold by Rexar for many years. In 1994, Richwood Pharmaceuticals acquired Rexar and began promoting Obetrol as a treatment for ADHD (and later narcolepsy as well), now marketed under the brand name of Adderall, a contraction of the phrase "A.D.D. for All" intended to convey that "it was meant to be kind of an inclusive thing" for marketing purposes.
酵素阻害剤
This proprietary mixture of amphetamine and dextroamphetamine salts (CAS Reg. Nos = 300-62-9 and 51-64-9; NLM Unique ID = C090411) is a CNS stimulant that is widely used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. These agents act by blocking the reuptake of dopamine and norepinephrine into presynaptic neurons and by stimulating the release of these monoamines into the synaptic cleft (See Amphetamine). Adderall is also used as a performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.
